Therapeutically, we demonstrate that the dual IR/IGF1R inhibitor linsitinib restored TKI sensitivity in vitro and synergized with surufatinib to reduce tumor burden and Ki-67 indices in an orthotopic model. Here, MKI67 is linked to neoplasm.